Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma
BackgroundThe overall 5-year survival of lung cancer was reported to be only ~15%, with lung adenocarcinoma (LUAD) as the main pathological subtype. Before developing into invasive stages, LUAD undergoes pre-invasive stages of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA),...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.921761/full |
| _version_ | 1811226936107597824 |
|---|---|
| author | Yue Zhao Yue Zhao Yue Zhao Jun Shang Jian Gao Jian Gao Jian Gao Han Han Han Han Han Han Zhendong Gao Zhendong Gao Zhendong Gao Yueren Yan Yueren Yan Yueren Yan Qiang Zheng Qiang Zheng Ting Ye Ting Ye Ting Ye Fangqiu Fu Fangqiu Fu Fangqiu Fu Chaoqiang Deng Chaoqiang Deng Chaoqiang Deng Zelin Ma Zelin Ma Zelin Ma Yang Zhang Yang Zhang Yang Zhang Difan Zheng Difan Zheng Difan Zheng Shanbo Zheng Shanbo Zheng Shanbo Zheng Yuan Li Yuan Li Zhiwei Cao Leming Shi Leming Shi Haiquan Chen Haiquan Chen Haiquan Chen |
| author_facet | Yue Zhao Yue Zhao Yue Zhao Jun Shang Jian Gao Jian Gao Jian Gao Han Han Han Han Han Han Zhendong Gao Zhendong Gao Zhendong Gao Yueren Yan Yueren Yan Yueren Yan Qiang Zheng Qiang Zheng Ting Ye Ting Ye Ting Ye Fangqiu Fu Fangqiu Fu Fangqiu Fu Chaoqiang Deng Chaoqiang Deng Chaoqiang Deng Zelin Ma Zelin Ma Zelin Ma Yang Zhang Yang Zhang Yang Zhang Difan Zheng Difan Zheng Difan Zheng Shanbo Zheng Shanbo Zheng Shanbo Zheng Yuan Li Yuan Li Zhiwei Cao Leming Shi Leming Shi Haiquan Chen Haiquan Chen Haiquan Chen |
| author_sort | Yue Zhao |
| collection | DOAJ |
| description | BackgroundThe overall 5-year survival of lung cancer was reported to be only ~15%, with lung adenocarcinoma (LUAD) as the main pathological subtype. Before developing into invasive stages, LUAD undergoes pre-invasive stages of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA), where surgical resection gives an excellent 5-year survival rate. Given the dramatic decline of prognosis from pre-invasive to invasive stages, a deeper understanding of key molecular changes driving the progression of LUAD is highly needed.MethodsIn this study, we performed whole-exome sequencing and RNA sequencing on surgically resected 24 AIS, 74 MIA, 99 LUAD specimens, and their adjacent paired normal tissues. Survival data were obtained by follow-up after surgery. Key molecular events were found by comparing the gene expression profiles of tumors with different stages. Finally, to measure the level of imbalance between tumor intrinsic growth potential and immune microenvironment, a tumor progressive (TP) index was developed to predict tumor progression and patients’ survival outcome and validated by external datasets.ResultsAs tumors progressed to more invasive stages, they acquired higher growth potential, mutational frequency of tumor suppressor genes, somatic copy number alterations, and tumor mutation burden, along with suppressed immune function. To better predict tumor progression and patients’ outcome, TP index were built to measure the imbalance between tumor intrinsic growth potential and immune microenvironment. Patients with a higher TP index had significantly worse recurrence-free survival [Hazard ratio (HR), 10.47; 95% CI, 3.21–34.14; p < 0.0001] and overall survival (OS) [Hazard ratio (HR), 4.83e8; 95% CI, 0–Inf; p = 0.0013]. We used The Cancer Genome Atlas (TCGA)-LUAD dataset for validation and found that patients with a higher TP index had significantly worse OS (HR, 1.10; 95% CI, 0.83–1.45; p = 0.048), demonstrating the prognostic value of the TP index for patients with LUAD.ConclusionsThe imbalance of tumor intrinsic growth potential and immune function orchestrate the progression of LUAD, which can be measured by TP index. Our study provided new insights into predicting survival of patients with LUAD and new target discovery for LUAD through assessing the imbalance between tumor intrinsic growth potential and immune function. |
| first_indexed | 2024-04-12T09:33:08Z |
| format | Article |
| id | doaj.art-112877eb71134117af90c39fe7dd4edf |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T09:33:08Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-112877eb71134117af90c39fe7dd4edf2022-12-22T03:38:17ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.921761921761Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung AdenocarcinomaYue Zhao0Yue Zhao1Yue Zhao2Jun Shang3Jian Gao4Jian Gao5Jian Gao6Han Han7Han Han8Han Han9Zhendong Gao10Zhendong Gao11Zhendong Gao12Yueren Yan13Yueren Yan14Yueren Yan15Qiang Zheng16Qiang Zheng17Ting Ye18Ting Ye19Ting Ye20Fangqiu Fu21Fangqiu Fu22Fangqiu Fu23Chaoqiang Deng24Chaoqiang Deng25Chaoqiang Deng26Zelin Ma27Zelin Ma28Zelin Ma29Yang Zhang30Yang Zhang31Yang Zhang32Difan Zheng33Difan Zheng34Difan Zheng35Shanbo Zheng36Shanbo Zheng37Shanbo Zheng38Yuan Li39Yuan Li40Zhiwei Cao41Leming Shi42Leming Shi43Haiquan Chen44Haiquan Chen45Haiquan Chen46Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaState Key Laboratory of Genetic Engineering, Human Phenome Institute, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaInternational Human Phenome Institutes (Shanghai), Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaSchool of Life Sciences, Fudan University, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaState Key Laboratory of Genetic Engineering, Human Phenome Institute, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, ChinaInstitute of Thoracic Oncology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaBackgroundThe overall 5-year survival of lung cancer was reported to be only ~15%, with lung adenocarcinoma (LUAD) as the main pathological subtype. Before developing into invasive stages, LUAD undergoes pre-invasive stages of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA), where surgical resection gives an excellent 5-year survival rate. Given the dramatic decline of prognosis from pre-invasive to invasive stages, a deeper understanding of key molecular changes driving the progression of LUAD is highly needed.MethodsIn this study, we performed whole-exome sequencing and RNA sequencing on surgically resected 24 AIS, 74 MIA, 99 LUAD specimens, and their adjacent paired normal tissues. Survival data were obtained by follow-up after surgery. Key molecular events were found by comparing the gene expression profiles of tumors with different stages. Finally, to measure the level of imbalance between tumor intrinsic growth potential and immune microenvironment, a tumor progressive (TP) index was developed to predict tumor progression and patients’ survival outcome and validated by external datasets.ResultsAs tumors progressed to more invasive stages, they acquired higher growth potential, mutational frequency of tumor suppressor genes, somatic copy number alterations, and tumor mutation burden, along with suppressed immune function. To better predict tumor progression and patients’ outcome, TP index were built to measure the imbalance between tumor intrinsic growth potential and immune microenvironment. Patients with a higher TP index had significantly worse recurrence-free survival [Hazard ratio (HR), 10.47; 95% CI, 3.21–34.14; p < 0.0001] and overall survival (OS) [Hazard ratio (HR), 4.83e8; 95% CI, 0–Inf; p = 0.0013]. We used The Cancer Genome Atlas (TCGA)-LUAD dataset for validation and found that patients with a higher TP index had significantly worse OS (HR, 1.10; 95% CI, 0.83–1.45; p = 0.048), demonstrating the prognostic value of the TP index for patients with LUAD.ConclusionsThe imbalance of tumor intrinsic growth potential and immune function orchestrate the progression of LUAD, which can be measured by TP index. Our study provided new insights into predicting survival of patients with LUAD and new target discovery for LUAD through assessing the imbalance between tumor intrinsic growth potential and immune function.https://www.frontiersin.org/articles/10.3389/fimmu.2022.921761/fullimbalancetumor intrinsic growth potentialimmune responseprogressionlung adenocarcinoma |
| spellingShingle | Yue Zhao Yue Zhao Yue Zhao Jun Shang Jian Gao Jian Gao Jian Gao Han Han Han Han Han Han Zhendong Gao Zhendong Gao Zhendong Gao Yueren Yan Yueren Yan Yueren Yan Qiang Zheng Qiang Zheng Ting Ye Ting Ye Ting Ye Fangqiu Fu Fangqiu Fu Fangqiu Fu Chaoqiang Deng Chaoqiang Deng Chaoqiang Deng Zelin Ma Zelin Ma Zelin Ma Yang Zhang Yang Zhang Yang Zhang Difan Zheng Difan Zheng Difan Zheng Shanbo Zheng Shanbo Zheng Shanbo Zheng Yuan Li Yuan Li Zhiwei Cao Leming Shi Leming Shi Haiquan Chen Haiquan Chen Haiquan Chen Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma Frontiers in Immunology imbalance tumor intrinsic growth potential immune response progression lung adenocarcinoma |
| title | Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma |
| title_full | Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma |
| title_fullStr | Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma |
| title_full_unstemmed | Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma |
| title_short | Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma |
| title_sort | increased tumor intrinsic growth potential and decreased immune function orchestrate the progression of lung adenocarcinoma |
| topic | imbalance tumor intrinsic growth potential immune response progression lung adenocarcinoma |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.921761/full |
| work_keys_str_mv | AT yuezhao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yuezhao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yuezhao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT junshang increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT jiangao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT jiangao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT jiangao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT hanhan increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT hanhan increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT hanhan increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT zhendonggao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT zhendonggao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT zhendonggao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yuerenyan increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yuerenyan increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yuerenyan increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT qiangzheng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT qiangzheng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT tingye increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT tingye increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT tingye increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT fangqiufu increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT fangqiufu increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT fangqiufu increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT chaoqiangdeng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT chaoqiangdeng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT chaoqiangdeng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT zelinma increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT zelinma increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT zelinma increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yangzhang increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yangzhang increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yangzhang increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT difanzheng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT difanzheng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT difanzheng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT shanbozheng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT shanbozheng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT shanbozheng increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yuanli increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT yuanli increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT zhiweicao increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT lemingshi increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT lemingshi increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT haiquanchen increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT haiquanchen increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma AT haiquanchen increasedtumorintrinsicgrowthpotentialanddecreasedimmunefunctionorchestratetheprogressionoflungadenocarcinoma |